Related Experiment Video
Updated: Jan 9, 2026

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
Published on: August 28, 2012
Prognostic Value of Tertiary Lymphoid Structures in Epithelial Ovarian Carcinoma
Takehiro Nakao1, Kenichi Harano2,3, Masashi Wakabayashi4
1Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Background/Aim:
Tertiary lymphoid structures (TLS) have become the focus of antitumor immunity. However, the prognostic significance of TLS in epithelial ovarian cancer (EOC) treated with primary debulking surgery (PDS) or interval debulking surgery (IDS) remains unclear. Therefore, we aimed to examine TLS in tumor tissues collected during PDS and IDS for patients with EOC to evaluate its prognostic significance.
Patients And Methods:
We examined TLS in EOC tumor tissues obtained during PDS or IDS from patients treated between 2017 and 2020 at the National Cancer Center Hospital East, Kashiwa, Japan. The association of tumor-infiltrating lymphocyte frequency, TLS presence, and programmed death-ligand 1 (PD-L1) expression with progression-free (PFS) and overall (OS) survival, and the association between TLS and PD-L1 expression were analyzed.
Results:
Overall, 25 specimens (15 from PDS and 10 from IDS) were analyzed. The presence of TLS was associated with a significantly longer OS (median: 32.3 vs. 21.3 months, p=0.0455) in patients who underwent PDS but not in patients who underwent IDS (median: could not be calculated, p=0.9678). No association was identified between TLS and PFS in patients with PDS or with IDS (median: 31.1 vs. 17.3 months, p=0.3970; median: 28.7 vs. 16.3 months for median without TLS, p=0.1653). However, TLS was positively correlated with PD-L1 positivity (p=0.0094).
Conclusion:
The prognostic impact of TLS, specifically in pre-chemotherapy specimens, and a positive association between TLS and PD-L1 indicate the potential of TLS as a meaningful biomarker for understanding antitumor immunity and developing immunotherapy for EOC.
More Related Videos
05:42Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
Published on: January 26, 2024
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010